Akeso’s Penpulimab-kcqx Receives the US FDA’s Approval for Nasopharyngeal Carcinoma (NPC)
Shots:
- The US FDA has approved penpulimab-kcqx + CT (cisplatin/carboplatin + gemcitabine) as 1L treatment for recurrent or metastatic non-keratinizing NPC in adults, & as monotx. for those with metastatic non-keratinizing NPC progressing on/after Pt-based CT & ≥1L prior therapy
- Approval was supported by 2 BLA submissions based on international P-III (AK105-304) trial & pivotal AK105-202 study assessing penpulimab-kcqx across two stages of metastatic NPC; data to be presented at AACR 2025
- Penpulimab-kcqx (PD-1 mAb) was initially developed by Akeso, with subsequent development & commercialization handled via a joint venture with Chia Tai-Tianqing Pharmaceutical Group
Ref: PRNewswire | Image: Akeso
Related News:- Akeso Reports First Patient Enrollment in P-III Study of Ivonescimab + CT to Treat Triple-Negative Breast Cancer (TNBC) in China
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
